BIOMAT Database Logo BIOMAT Database Logo

Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo-[4,5,1-jk][1,4]benzodiazepin- 2(1H)-one (TlBO) derivatives. 4. 1995

W Ho, and M J Kukla, and H J Breslin, and D W Ludovici, and P P Grous, and C J Diamond, and M Miranda, and J D Rodgers, and C Y Ho, and E De Clercq
Janssen Research Foundation, Spring House, Pennsylvania 19477.

In previous papers, we have described the discovery of a new series of compounds, 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1 H)- ones, TlBO (1 and 1a), with potent anti-HIV-1 activity and the synthesis of analogues to better define the structure-activity relationships (SAR) in terms of changes in substituents at the N-6 position and variations of the five-membered urea ring as well as the seven-membered diazepine ring. This paper describes the synthesis of TlBO analogues with various substitutents on the aromatic ring and their SAR in terms of anti-HIV-1 properties. Substituents on the 8-position furnished the most rewarding results and gave a large improvement in potency versus the parent compound. These included halogen, thiomethyl, and methyl. Analogues like 8-cyano, -methoxy, and -acetylene were equipotent, while 8-amino, -acetylamino, -dimethylamino, and -nitro were inactive (Table 1). Substituents at the 9-position tended to have little effect on activity, and 10-substituents decreased activity. The 8-chloro compound 6a with IC50 = 0.0043 microM is currently under clinical development.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003588 Cytopathogenic Effect, Viral Visible morphologic changes in cells infected with viruses. It includes shutdown of cellular RNA and protein synthesis, cell fusion, release of lysosomal enzymes, changes in cell membrane permeability, diffuse changes in intracellular structures, presence of viral inclusion bodies, and chromosomal aberrations. It excludes malignant transformation, which is CELL TRANSFORMATION, VIRAL. Viral cytopathogenic effects provide a valuable method for identifying and classifying the infecting viruses. Cytopathic Effect, Viral,Viral Cytopathogenic Effect,Cytopathic Effects, Viral,Cytopathogenic Effects, Viral,Effect, Viral Cytopathic,Effect, Viral Cytopathogenic,Effects, Viral Cytopathic,Effects, Viral Cytopathogenic,Viral Cytopathic Effect,Viral Cytopathic Effects,Viral Cytopathogenic Effects
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D001569 Benzodiazepines A group of two-ring heterocyclic compounds consisting of a benzene ring fused to a diazepine ring. Benzodiazepine,Benzodiazepine Compounds
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human

Related Publications

W Ho, and M J Kukla, and H J Breslin, and D W Ludovici, and P P Grous, and C J Diamond, and M Miranda, and J D Rodgers, and C Y Ho, and E De Clercq
Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin- 2(1H)-one (TIBO) derivatives.
February 1991, Journal of medicinal chemistry,
W Ho, and M J Kukla, and H J Breslin, and D W Ludovici, and P P Grous, and C J Diamond, and M Miranda, and J D Rodgers, and C Y Ho, and E De Clercq
Synthesis and anti-HIV activity of 1,3,4,5-tetrahydro-2H-1,4-benzodiazepin-2-one (TBO) derivatives. Truncated 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2( 1H)-on es (TIBO) analogues.
November 1999, Bioorganic & medicinal chemistry,
W Ho, and M J Kukla, and H J Breslin, and D W Ludovici, and P P Grous, and C J Diamond, and M Miranda, and J D Rodgers, and C Y Ho, and E De Clercq
From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.
March 2005, Journal of medicinal chemistry,
W Ho, and M J Kukla, and H J Breslin, and D W Ludovici, and P P Grous, and C J Diamond, and M Miranda, and J D Rodgers, and C Y Ho, and E De Clercq
Synthesis and study of anti-HIV-1 RT activity of 5-benzoyl-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one derivatives.
June 2017, Bioorganic chemistry,
W Ho, and M J Kukla, and H J Breslin, and D W Ludovici, and P P Grous, and C J Diamond, and M Miranda, and J D Rodgers, and C Y Ho, and E De Clercq
Solid-phase synthesis of tetrahydro-1,4-benzodiazepin-2-one derivatives.
January 2000, Molecular diversity,
W Ho, and M J Kukla, and H J Breslin, and D W Ludovici, and P P Grous, and C J Diamond, and M Miranda, and J D Rodgers, and C Y Ho, and E De Clercq
Synthesis and pharmacological activity and some derivatives of 1-phenyl-1,2,3,4-tetrahydro-5H-1,4-benzodiazepin-5-one.
May 1978, Journal of medicinal chemistry,
W Ho, and M J Kukla, and H J Breslin, and D W Ludovici, and P P Grous, and C J Diamond, and M Miranda, and J D Rodgers, and C Y Ho, and E De Clercq
Synthesis and pharmacological properties of new derivatives of 4-methyl-5-oxalo-1H-2,3,4,5-tetrahydro-1,5-benzodiazepin-2-one and beta-oxo-5-(4-methyl-1H-2,3,4,5-tetrahydro-1,5-benzodiazepin-2 -one)propionic acid.
January 1996, Acta poloniae pharmaceutica,
W Ho, and M J Kukla, and H J Breslin, and D W Ludovici, and P P Grous, and C J Diamond, and M Miranda, and J D Rodgers, and C Y Ho, and E De Clercq
An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives.
February 1991, Proceedings of the National Academy of Sciences of the United States of America,
W Ho, and M J Kukla, and H J Breslin, and D W Ludovici, and P P Grous, and C J Diamond, and M Miranda, and J D Rodgers, and C Y Ho, and E De Clercq
Allosteric inhibition of human immunodeficiency virus type 1 reverse transcriptase by tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione compounds.
January 1992, Molecular pharmacology,
W Ho, and M J Kukla, and H J Breslin, and D W Ludovici, and P P Grous, and C J Diamond, and M Miranda, and J D Rodgers, and C Y Ho, and E De Clercq
A novel one-pot pseudo-five-component synthesis of 4,5,6,7-tetrahydro-1H-1,4-diazepine-5-carboxamide derivatives.
May 2008, The Journal of organic chemistry,
Copied contents to your clipboard!